Learn to Customize Your Own Options Trading Strategy
This guide will help you evaluate and analyze your trading plan to create a custom options trading strategy tailored to your risk profile and market outlook. Learn how to take your trading to the next level.
Download your FREE Options Strategy Guide Today!
Ramesh Kumar, insider at Ocugen
Ramesh Kumar Insider Alerts

Get notified the next time Ramesh Kumar buys or sells Ocugen stock. Enter your email address below to get our daily insider buying and selling report.

Ramesh Kumar Insider Information

Director of Ocugen
Dr. Ramesh Kumar Ph.D. serves as Independent Director of the Company. Dr. Kumar has served as a director of OpCo, our wholly owned subsidiary, since June 2019. He co-founded Onconova Therapeutics, Inc. in 1998 and served as its Chief Executive Officer and a member of its board from 1998 to February 2019 and as its President from 1998 to June 2018. Dr. Kumar transitioned to an Advisory role with Onconova in January 2019. He has held positions in R&D and management at Princeton University, Bristol-Myers Squibb, DNX (later Nextran, a subsidiary of Baxter) and Kimeragen (later Valigen), where he served as President of the Genomics and Transgenics Division. Dr. Kumar obtained an undergraduate and Master’s degree in Microbiology from Panjab University and received his Ph.D. in Molecular Biology from the University of Illinois, Chicago and trained at the National Cancer Institute. Our Board believes Dr. Kumar’s extensive senior executive and public company experience, and familiarity with the pharmaceutical industry qualify him to serve on our Board.

What is Ramesh Kumar's net worth?

The estimated net worth of Ramesh Kumar is at least $43,200.00 as of July 19th, 2021. Dr. Kumar owns 7,500 shares of Ocugen stock worth more than $43,200 as of December 5th. This net worth approximation does not reflect any other investments that Dr. Kumar may own. Learn More.

How do I contact Ramesh Kumar?

The corporate mailing address for Dr. Kumar and other Ocugen executives is 5 GREAT VALLEY PARKWAY V, MALVERN PA, 19355. Ocugen can also be reached via phone at (484) 328-4701 and via email at [email protected]

Has Ramesh Kumar been buying or selling shares of Ocugen?

Ramesh Kumar has not been actively trading shares of Ocugen over the course of the past ninety days. Most recently, Ramesh Kumar sold 7,500 shares of the business's stock in a transaction on Monday, July 19th. The shares were sold at an average price of $6.40, for a transaction totalling $48,000.00. Following the completion of the sale, the director now directly owns 7,500 shares of the company's stock, valued at $48,000.

Who are Ocugen's active insiders?

Ocugen's insider roster includes Kirsten Castillo (Director), Prabhavathi Fernandes (Director), Uday Kompella (Director), Ramesh Kumar (Director), Shankar Musunuri (CEO), Manish Potti (Director), Sanjay Subramanian (CFO), and Vijay Tammara (SVP).

Are insiders buying or selling shares of Ocugen?

In the last twelve months, insiders at the sold shares 32 times. They sold a total of 1,840,106 shares worth more than $20,689,437.22. The most recent insider tranaction occured on November, 16th when CEO Shankar Musunuri sold 115,000 shares worth more than $924,600.00. Insiders at Ocugen own 3.7 % of the company.

Information on this page was last updated on 11/16/2021.

Ramesh Kumar Insider Trading History at Ocugen

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/19/2021Sell7,500$6.40$48,000.007,500View SEC Filing Icon  
4/19/2021Sell7,500$5.33$39,975.007,500View SEC Filing Icon  
See Full Table

Ramesh Kumar Buying and Selling Activity at Ocugen

This chart shows Ramesh Kumar's buying and selling at Ocugen by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Ocugen Company Overview

Ocugen logo
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.
Read More

Today's Range

Now: $5.76
Low: $5.65
High: $6.40

50 Day Range

MA: $8.41
Low: $5.76
High: $15.67

2 Week Range

Now: $5.76
Low: $0.28
High: $18.77

Volume

16,970,472 shs

Average Volume

46,767,520 shs

Market Capitalization

$1.15 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

4.5
Learn to Customize Your Own Options Trading Strategy
This guide will help you evaluate and analyze your trading plan to create a custom options trading strategy tailored to your risk profile and market outlook. Learn how to take your trading to the next level.
Download your FREE Options Strategy Guide Today!